

PRESS RELEASE, 15 October 2018



Iconovo signs an agreement with McMaster University for development of vaccine against tuberculosis

The innovative Swedish medical technology company Iconovo AB announced today that the company has signed a partnership agreement with McMaster University in Canada. The agreement relates to the development of a dry powder preparation of inhalable vaccine against tuberculosis to be used in Iconovo's unique single-dose inhaler ICOone.

Iconovo will be part of a multidisciplinary research and development project aimed at developing next-generation virus-based powder vaccine that is stable at room temperature. Being able to transport vaccines without the need for cold storage is a prerequisite for quickly and efficiently reaching out to the people who need it the most. In the current project, Iconovo's unique disposable ICOone inhaler will be used as a test platform to facilitate future commercialization and large-scale manufacturing. The project is planned to last for three years and is partly financed by the Canadian state (CIHR / NSERC).

Tuberculosis occurs throughout the world and is one of the ten most common causes of death. According to the World Health Organization (WHO), 10 million people were affected by tuberculosis in 2017, of which 1 million children. In 2017, 1.6 million died of the disease.

"This is a very important first step towards being able to offer a safe, effective and affordable tuberculosis vaccine. We are extremely pleased to collaborate with some of the world's top researchers in the field and proud they have chosen to work with our ICOone", says Orest Lastow, CEO Iconovo.

"The research team at McMaster, composed of world leading immunologists and engineers who will develop the vaccines, is excited by this opportunity to work with the design talent of Iconovo in inhaler products to address critical deficiencies in global immunization programs as described by the World Health Organization", says Professor Michael Thompson, Project Manager at McMaster University.

For further information, please contact:

Orest Lastow, CEO, orest.lastow@iconovo.se, mobile: 076-5422220.

About McMaster University

Founded in 1887, McMaster University is one of Canada's four universities with six faculties and over 30,000 students. The university conducts world-leading research in, among other things, inhaled drugs. It is ranked 77th in the world by Times Higher Education World University Rankings.

About ICOone

ICOone is a small disposable inhaler containing a single dose of a drug in the form of dry powder. ICOone is especially suitable for vaccines since, on the contrary to injectable vaccines, it does not require cold storage or assistance of medically trained personnel. The use of ICOone also does not give rise to any hazardous waste.

About Iconovo AB

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at www.iconovo.se.

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North, Stockholm since April 6, 2018. Erik Penser Bank AB is the Company's Certified Adviser.

Iconovo AB is required to publish this information based on the EU Market Abuse Regulation. The information was provided by the contact person below for publication on [xx] June 2018 at 08.00 CET.